Legal & General Group PLC Precigen, Inc. Transaction History

Legal & General Group PLC

$470 Billion
Q3 2024

A detailed history of Legal & General Group PLC transactions in Precigen, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 10,918 shares of PGEN stock, worth $8,952. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,918

Previous 10,918 -0.0%

Holding current value

$8,952

Previous $10,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 15, 2024	SELL	$0.89 - $1.41 $1,575 - $2,495	-1,770 Reduced 13.95%	10,918 $14,000
Q2 2023 Aug 14, 2023	SELL	$0.96 - $1.4 $10,102 - $14,732	-10,523 Reduced 45.34%	12,688 $14,000
Q1 2023 May 15, 2023	SELL	$0.88 - $2.19 $17,323 - $43,112	-19,686 Reduced 45.89%	23,211 $24,000
Q3 2022 Nov 14, 2022	SELL	$1.41 - $2.79 $38,901 - $76,976	-27,590 Reduced 39.14%	42,897 $92,000
Q2 2022 Aug 22, 2022	BUY	$1.15 - $2.53 $7,793 - $17,145	6,777 Added 10.64%	70,487 $94,000
Q4 2021 Feb 14, 2022	BUY	$3.53 - $5.5 $476 - $742	135 Added 0.21%	63,710 $236,000
Q3 2021 Nov 15, 2021	BUY	$4.99 - $6.55 $89,964 - $118,089	18,029 Added 39.58%	63,575 $317,000
Q2 2021 Aug 12, 2021	BUY	$6.24 - $8.22 $14,969 - $19,719	2,399 Added 5.56%	45,546 $297,000
Q1 2021 May 17, 2021	BUY	$6.74 - $10.95 $100,439 - $163,176	14,902 Added 52.76%	43,147 $297,000
Q3 2020 Nov 13, 2020	SELL	$3.5 - $6.2 $10,356 - $18,345	-2,959 Reduced 9.48%	28,245 $98,000
Q2 2020 Aug 14, 2020	BUY	$2.16 - $5.46 $492 - $1,244	228 Added 0.74%	31,204 $155,000
Q1 2020 May 14, 2020	BUY	$1.46 - $7.19 $45,224 - $222,717	30,976 New	30,976 $105,000

Others Institutions Holding PGEN

# of Institutions

144

Shares Held

159M

Call Options Held

232K

Put Options Held

69K

View Full List

About PRECIGEN, INC.

Ticker PGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 208,150,000
Market Cap $171M
Description
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...

More about PGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Precigen, Inc. Transaction History